NCI Community Oncology Research Program
Community Oncology and Prevention Trials
SWOG Cancer Research Network
For more information, see ClinicalTrials.gov NCT04435756
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Biomarker Analysis, Blood Product Collection
Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Craig R Nichols, Jay W. Carlson, Lisa Bailey, Brian R. Hu, Kendrith M. Rowland, Bryan A. Faller, Mark F. Kozloff, Nabil Adra, Preston D. Steen, Paul M. Barr, Christopher H. Chay, Timothy D. Moore, Abdul Hai Mansoor, Christopher W. Ryan, Rubina Qamar, Edward P. Gelmann, Frederick E. Millard, Siamak Daneshmand, Jeffrey L. Berenberg, Scott E. Delacroix, Bruce J. Roth, Thomas L. Jang, Andrea L. Harzstark, Shilajit Kundu, Bret E. Friday, Thomas P. Bradley, John A. Ellerton, Nicholas G. Cost, Abhinav Sidana, Lucia Nappi, Kimberly M. Hagel, Kathleen J. Yost, Sunil Parimi, Helen H. Moon, Mark S. Litwin, Scott E. Eggener, Neda Hashemi Sadraei, Kelly L. Stratton, Asit K. Paul, Ahmad Shabsigh, Natasha M. Tiffany, Anupam Batra, Seth O. Fagbemi, Joshua Lukenbill, Benjamin A. Teply, Ki Y. Chung, Huong T. Pham, Naveen S. Basappa, Daygen Finch, Lori A. Wood, Robert J. Hamilton, Isaac A. Bowman, Matthew L. Ryan, Site Public Contact, Sean Q. Kern, Brian I. Rini, Eric W. Winquist, Amer Sami, Charles F. Polotti, Arash Rezazadeh Kalebasty, Xiaosong Meng, Yousef Zakharia, Gregory A. Masters, Nimira S. Alimohamed